Twenty-four percent of US adolescent treatment centers do not use a “lifesaving” medication. An article appeared today in the Journal of the American Medical Association titled “Treatments Used Among ...
Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients ...
Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...
The findings, which appeared today in JAMA Network Open, are strong evidence that buprenorphine, a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder, can be ...
In a clinical trial, a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of ...
Please provide your email address to receive an email when new articles are posted on . The study included 227 individuals with OUD given CAM2038 either on weekly or monthly basis. The treatment was ...
13d
Spokane's Deaconess Hospital starts program to combat drug withdrawal with long-lasting medication
A pilot program from MultiCare Deaconess Hospital now provides long lasting opioid withdrawal medication. The injectable buprenorphine will provide a much more stable basis for patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results